Elusys Therapeutics, Inc. recently received $16.35 million for completing the second delivery of ANTHIM injection for the treatment of anthrax exposure.
The funds are part of a $45 million procurement contract to provide the treatment for the U.S. Strategic National Stockpile (SNS). Elusys previously received $8 million for its delivery on ANTHIM in early 2016.
The treatment received marketing approval in March 2016 by the U.S. Food and Drug Administration and has been indicated for use in adult and pediatric patients for the treatment of inhalation anthrax i combination with appropriate antibacterial drugs. It is also indicated for prophylaxis of inhalation anthrax when alternative therapies are neither available or appropriate.
The company also announced that it has been awarded approximately $5 million of additional funding from the Biomedical Advanced Research and Development Authority to continue its lyophilization development program and regulatory activities to support a supplemental BLA for lyophilized, or freeze-dried, form of ATHIM. In total, Elusys has received authorized funding of more than $200 million under the two advanced development contracts for ANTHIM.
Anthrax is a life threatening infection caused by Bacillus anthracis, which is commonly used as a form of bioterrorism. Exposure to anthrax is deadly in humans.
Elusys Therapeutics is a biopharmaceutical company focused on the development of antibody therapeutics for the treatment of infectious diseases.